Ongoing global studies have found that pregnant women are more likely to develop severe COVID-19 disease compared to non-pregnant women of the same age. Pregnant women who develop COVID-19 symptoms are two to three times more likely to have their baby early. For these reasons, the national recommendation in the UK is that COVID-19 vaccination should be offered to pregnant women at the same time as the rest of the population. However, further pregnancy-specific research into COVID-19 vaccines is urgently needed.

The number of COVID-19 vaccines given in this study would depend on what you have already received and are currently eligible for. There is also an observational cohort for participants who are not due any further doses but have received a dose during pregnancy.

Some participants may be offered a third or fourth booster as a fractional dose of the COVID-19 booster (full dose Pfizer, half dose Pfizer, half dose Moderna) and for it to be co-administered with routine antenatal vaccinations (e.g. whooping cough vaccine).

There will be a minimum of seven routine study visits and participants will be followed up until one year after their baby’s birth. The majority of visits will happen at hospital and participants will be reimbursed up to £45 per visit.

Blood samples will be taken from participants throughout the study. A baby blood sample will be taken when babies are between 4-12 weeks old. Participants will also be asked to complete a symptom diary following vaccination or if they become symptomatic for COVID-19.

• Women who have had a normal dating scan in pregnancy
• Aged 18-years or older
• Generally fit and well

Please download and read the Participant Information Sheet, and contact the trial team here.